Bapotulimab

• CAT Number: I042164
• CAS Number: 2359413-58-2
• Purity: ≥95%

Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects[1].
Bapotulimab blocks the immunosuppressive effects of ILDR2 on T-cell activation. Bapotulimab is mouse/human cross-reactive, as ILDR2 has a 98% sequence identity between the extracellular domains of human and murine orthologs[1].
Bapotulimab (BAY-1905254; 5, 25, 100, or 500 ng/mL) promotes T-cell activation in vitro and enhance antigen-specific T-cell proliferation[1].
Bapotulimab (BAY-1905254; 10 mg/kg; i.p.; on days 1 and 4) shows significantly increased antigen-specific T-cell proliferation and cytotoxicity[1].

Reference

[1]. Julia Huetter, et al. Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020 Jul;8(7):895-911.
 [Content Brief]